Company: LCTX
Filing Date: 2025-06-09
Form Type: 8-K
Source: 0000950170-25-083866
Chunk: 0

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-06-09
Form: 8-K
Item: Item 4.01
Chunk 0
---
Item 4.01 Changes in Registrant’s Certifying Accountant.

On June 3, 2025, Lineage Cell Therapeutics, Inc., (the “ Company”) was notified that Moss Adams LLP (“ Moss Adams”), the Company's independent registered public accounting firm, merged with Baker Tilly US, LLP (“ Baker Tilly”), effective on June 3, 2025, and that the combined audit practices operate as Baker Tilly. In connection with the notification of the merger, Moss Adams resigned as the auditors of the Company and the Audit Committee of the Company’s Board of Directors (the “ Audit Committee”) approved the appointment of Baker Tilly, as the successor to Moss Adams, as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

The Audit Committee appointed Moss Adams as the Company’s independent registered public accounting firm on June 11, 2024. The audit report of Moss Adams on the Company’s consolidated financial statements for the year ended December 31, 2024, did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope or accounting principles. During the year ended December 31, 2024, and from December 31, 2024 through June 3, 2025, there were no (i) disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) between the Company and Moss Adams on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Moss Adams, would have caused Moss Adams to make reference to the subject matter of such disagreements in connection with its report, or (ii) “reportable events,” as described in Item 304(a)(1)(v) of Regulation S-K, that would require disclosure under Item 304(a)(1)(v) of Regulation S-K.

During the Company’s two most recent fiscal years and from December 31, 2024 through June 3, 2025, neither the Company, nor any person acting on its behalf, consulted Baker Tilly regarding (i) the application of accounting principles to a specified transaction, either completed or proposed, (ii) the type of the audit opinion that might be rendered on the Company’s financial statements, and Baker Tilly did not provide any written report or oral advice to the Company that Baker